"Increased profitability and strong operational performance"
Summary first quarter 2024
January - March
- Total revenues amounted to
SEK 390 (284) million, an increase of 37% (38% at CER1) -
Product sales of Buvidal® were
SEK 364 (282) million, an increase of 29% (30% at CER1), and 0% (3% at CER1) compared to previous quarter -
Brixadi® US royalties increased from
SEK 8 to 26 million, an increase of 212% (193% at CER1) -
Operating result was
SEK 79 (74) million, an increase of 7% -
Profit before tax was
SEK 97 (77) million, an increase of 26% -
Directed share issue carried out with net proceeds of
SEK 1,026 million -
Cash position at the end of the quarter was
SEK 2,274 (586) million - Financial guidance for the full year 2024 reiterated
-
New Drug Application (NDA) for Oclaiz™ (CAM2029) in acromegaly accepted for review by the
US FDA with PDUFA action date21 October, 2024 - Recruitment completed in the POSITANO study of CAM2029 in patients with polycystic liver disease
Camurus established its US office in the Carnegie Center,Princeton, NJ , USCamurus moved to Nasdaq Stockholm Large Cap segment
Significant events after the period
- A Market Authorization Application (MAA) for CAM2029 for the treatment of acromegaly submitted to the
European Medicines Agency (EMA)
Financial summary first quarter 2024
- Total revenue
SEK 390 (284) million
- whereof product salesSEK 364 (282) million -
OPEX
SEK -289 (-184) million -
Operating result
SEK 79 (74) million -
Profit before tax
SEK 97 (77) million -
Result for the period
SEK 78 (59) million -
Earnings per share, after dilution, of
SEK 1.32 (1.02) -
Cash position
SEK 2,274 (586) million
1. At constant exchange rates
"
Audiocast
Financial analysts and media are invited to attend a telephone conference and presentation of the results today at
For more information:
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
About
This information is information that
https://news.cision.com/camurus-ab/r/camurus--interim-report-january-march-2024,c3975114
https://mb.cision.com/Main/13456/3975114/2784764.pdf
(c) 2024 Cision. All rights reserved., source